Saturday, June 20, 2026

Patent directory · USPTO A61K / A61P

Browse patents

Browse 30,257 pharma-relevant patents (US A61K/A61P) linked to tracked companies, drugs, and pipeline programs.

Patents indexed 30,257
Companies 1,769
Drugs linked 4,797

Quick answer

NovaPharmaNews indexes 30,257 US pharmaceutical patents from USPTO PatentsView (CPC A61K/A61P), cross-linked to company assignees, drug INN profiles, and pipeline programs. Search by patent number, applicant, title, or CPC code — or use facet hubs for expiring patents, assignees, and therapeutic areas.

Patent results

Page 73 of 1,261
  1. US 12180296

    Cross species single domain antibodies targeting mesothelin for treating solid tumors

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Dec 31, 2024 · Expires Dec 26, 2044

    granted
  2. US 12178417

    Devices and methods for umbilical cord processing

    The Board of Regents of the University of Texas System · Granted Dec 31, 2024 · Expires Dec 26, 2044

    granted
  3. US 12178823

    Methods for treating subjects with Prader-Willi syndrome or Smith-Magenis syndrome

    ESSENTIALIS, INC. · Granted Dec 31, 2024 · Expires Dec 26, 2044

    granted
  4. US 12180251

    Nucleic acids encoding peptides that block binding of a2d-1 to glutamate receptors for treating diseases and disorders

    The Board of Regents of the University of Texas System · Granted Dec 31, 2024 · Expires Dec 26, 2044

    granted
  5. US 12180463

    Lactobacillus reuteri

    PrecisionBiotics Group Limited · Granted Dec 31, 2024 · Expires Dec 26, 2044

    granted
  6. US 12180509

    Methods for reprograming non-pluripotent cells into pluripotent stem cells

    BeiHao Stem Cell and Regenerative Medicine Research Institute Co., Ltd. · Granted Dec 31, 2024 · Expires Dec 26, 2044

    granted
  7. US 12180479

    Compounds and methods for modulating ATXN1

    Ionis Pharmaceuticals, Inc. · Granted Dec 31, 2024 · Expires Dec 26, 2044

    granted
  8. US 12180503

    Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription

    The Regents of the University of California · Granted Dec 31, 2024 · Expires Dec 26, 2044

    granted
  9. US 12181485

    Methods of blood screening

    CASI Pharmaceuticals, Inc · Granted Dec 31, 2024 · Expires Dec 26, 2044

    granted
  10. US 12180206

    Aceclidine derivatives, compositions thereof and methods of use thereof

    LENZ THERAPEUTICS OPERATIONS, INC. · Granted Dec 31, 2024 · Expires Dec 26, 2044

    granted
  11. US 12181555

    3-dimensional representations of post-contrast enhanced brain lesions

    The Board of Regents of the University of Texas System · Granted Dec 31, 2024 · Expires Dec 26, 2044

    granted
  12. US 12180504

    Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription

    The Regents of the University of California · Granted Dec 31, 2024 · Expires Dec 26, 2044

    granted
  13. US 12180258

    T-cell modulatory multimeric polypeptides and methods of use thereof

    Cue Biopharma, Inc. · Granted Dec 31, 2024 · Expires Dec 26, 2044

    granted
  14. US 12180272

    Antigen binding molecule formats

    REGENERON PHARMACEUTICALS, INC. · Granted Dec 31, 2024 · Expires Dec 26, 2044

    granted
  15. US 12180277

    LILRB4-binding antibody and methods of use thereof

    The Board of Regents of the University of Texas System · Granted Dec 31, 2024 · Expires Dec 26, 2044

    granted
  16. US 12180484

    Chimeric antigen receptors targeting B-cell maturation antigen

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Dec 31, 2024 · Expires Dec 26, 2044

    granted
  17. US 12178848

    Methods and compositions for the treatment of exocrine pancreatic insufficiency

    The Board of Regents of the University of Texas System · Granted Dec 31, 2024 · Expires Dec 26, 2044

    granted
  18. US 12178981

    Drug administration method

    Takeda Pharmaceutical Company Limited · Granted Dec 31, 2024 · Expires Dec 26, 2044

    granted
  19. WO 2024261256

    COMPOSITION PHARMACEUTIQUE COMPRENANT UN AGENT DE DÉGRADATION PAN-KRAS

    ASTELLAS PHARMA INC [JP] · Granted Dec 26, 2024 · Expires Dec 21, 2044

    granted
  20. WO 2024261235

    PROTÉINES CHIMÉRIQUES POUR MODULER L'ACTIVITÉ D'UN RÉCEPTEUR DE CYTOKINE

    ABLYNX NV [BE] · Granted Dec 26, 2024 · Expires Dec 21, 2044

    granted
  21. US 12173062

    Modified TNF-α antibodies and uses thereof

    Bright Peak Therapeutics AG · Granted Dec 24, 2024 · Expires Dec 19, 2044

    granted
  22. US 12173087

    Melanocortin 1 receptor ligands and methods of use

    Arizona Board of Regents on Behalf of the University of Arizona · Granted Dec 24, 2024 · Expires Dec 19, 2044

    granted
  23. US 12173274

    Enhanced immune effector cells and use thereof

    Fate Therapeutics, Inc. · Granted Dec 24, 2024 · Expires Dec 19, 2044

    granted
  24. US 12173088

    Anti-microbial peptides

    BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA · Granted Dec 24, 2024 · Expires Dec 19, 2044

    granted

Frequently asked questions

What patents are included in this directory?

We index 30,257 published US pharma-relevant patents filtered to CPC classes A61K and A61P, with assignee links to our company directory where a match exists.

How do I search for a patent?

Use the search box to match patent number, title, applicant name, or CPC classification (e.g. A61K). For cross-entity queries spanning news and drugs, use the global search.

How is this different from the patent intelligence dashboard?

The dashboard at /patents highlights expirations, recent grants, and assignee rankings. Browse is the full paginated directory with search — best for looking up a specific filing or applicant portfolio slice.